Paul L Berns
CIK 1202769 · See Remarks · last filed 2026-08-21
Paul L Berns is a corporate insider who has filed 101 SEC Form 4 insider transactions across 13 companies since 2007. The most recent filing, for NMRA, was dated Aug 21, 2026. Across all open-market trades the lifetime net is +$122.0M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $236.9M across reported positions. 2 SEC filings were submitted jointly with ARCH Venture Fund XIII, L.P.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
Filer Profile
260 ARSENAL PLACE, SUITE 1
WATERTOWN, MA 02472
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NMRA | See Remarks | 7,528,282 | $0.50 | $3.76M | -$57.9K | 8 | 2026-08-21 |
| KARD | Director | 15,062,741 | $14.79 | $222.78M | $20.00M | 2 | 2026-06-24 |
| LYEL | 10%+ Owner | 910,317 | $9.26 | $8.43M | $112.50M | 1 | 2026-03-09 |
| Metsera, Inc. (MTSR) Delisted | Director | 0 | $70.50 | $0 | $14.22M | 3 | 2025-11-13 |
| Unity Biotechnology, Inc. (UBX) Delisted | Director | 326 | $0.20 | $65 | $0 | 7 | 2024-06-21 |
| EQRx, Inc. (EQRXW) Delisted | Director | 0 | $0.05 | $0 | $0 | 4 | 2023-11-09 |
| JAZZ | Director | 8,290 | $235.67 | $1.95M | -$3.76M | 23 | 2021-08-09 |
| VYNE Therapeutics Inc. (MNLO) Delisted | Director | — | — | — | $0 | 2 | 2019-08-08 |
| Anacor Pharmaceuticals, Inc. (ANAC) Delisted | President and CEO | 0 | $10.19 | $0 | -$16.52M | 14 | 2016-06-24 |
| XENOPORT INC (XNPT) Delisted | Director | 15,000 | — | — | -$525.2K | 10 | 2016-05-19 |
| Cellectar Biosciences, Inc. (CLRB.Z) Delisted | Director | 117,371 | — | — | $248.8K | 1 | 2016-04-21 |
| Cellectar Biosciences, Inc. (CLRB.W) Delisted | Director | — | — | — | $0 | 2 | 2015-06-10 |
| ALLOS THERAPEUTICS INC (ALTH) Delisted | Chief Executive Officer | 0 | — | — | -$4.14M | 22 | 2012-09-05 |
Recent Filings
101 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-08-21 | NMRA | Grant (A) | — | $0 | EDGAR |
| 2026-06-24 | KARD | Buy (P) | +1,250,000 | $20.00M | EDGAR |
| 2026-06-22 | KARD | Mixed | +13,812,741 | $0 | EDGAR |
| 2026-03-09 | LYEL | Buy (P) | +4,392,810 | $112.50M | EDGAR |
| 2026-02-19 | NMRA | Sell (S) | −9,819 | -$34.5K | EDGAR |
| 2026-02-17 | NMRA | Notice (144) | −9,819 | -$34.5K | EDGAR |
| 2026-01-09 | NMRA | Grant (A) | — | $0 | EDGAR |
| 2025-11-13 | Metsera, Inc. (MTSR) Delisted | Mixed | −16,798,952 | $0 | EDGAR |
| 2025-05-30 | NMRA | Mixed | — | $0 | EDGAR |
| 2025-05-22 | Metsera, Inc. (MTSR) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.